HomeFile

File

View Category
Antiplatelet

The FDA Approves Ticagrelor for Primary Prevention in High Risk Patients

The FDA has approved the indication of ticagrelor as primary prevention in high risk CAD patients with...
solaci -
Learn More
Chronic Ischemic cardiopathy

Stenting of Lipid-Rich vs Fibrous and calcified Plaques: Different Prognosis?

Coronary PCI with contemporary drug eluting stents (DES) in lipidic-rich plaques were not associated with increased periprocedural...
solaci -
Learn More
Structural heart disease

Self-Expanding Valve vs. Balloon-Expandable Valve, Randomized, Head to Head

The “arms race”among transcatheter valves has been vertiginous. By the time we received the mid- or long-term...
solaci -
Learn More
Chronic Ischemic cardiopathy

Non-Invasive Diagnosis of Coronary Spasm: Can We Recommend it?

Conventional non-invasive testing to detect obstructive coronary artery disease (CAD) by induced myocardial ischemia are not useful...
solaci -
Learn More
Coronary disease

Is the Use of iFR for the Deferral of Left Main Coronary Artery Lesions Safe?

Deferral of left main coronary artery lesions using instantaneous wave-free ratio (iFR) seems to be safe. At...
solaci -
Learn More
Acute coronary syndromes

Optimal Intervention Timing for NSTEMI with No Antiaggregant Pre-Treatment

Patients undergoing non-ST elevation MI (NSTEMI) who are not pre-treated with P2Y12 receptor inhibitors will benefit from...
solaci -
Learn More
Acute coronary syndromes

Multiple vs. Culprit vessel MI in Cardiogenic Shock: Anything New?

The Shock Trial, the one that set revascularization as the standard strategy to treat all STEMI and...
solaci -
Learn More
Coronary disease

Estimating the Risk of Infection for Healthcare Personnel

Roughly one out of every 100 healthcare workers at hospitals receiving COVID-19 patients become infected. Statistics are not...
solaci -
Learn More